Associated Papers
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers.
Katayama N et al.
British Journal of Clinical Pharmacology, 2021
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2016
Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
Backman JT et al.
Pharmacological Reviews, 2016
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Genetic polymorphisms of CYP2C8 in the Czech Republic.
Pechandova K et al.
Genetic Testing and Molecular Biomarkers, 2012
Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8.
Jiang H et al.
Amino Acids, 2011
Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.
Kaspera R et al.
Pharmacogenetics and Genomics, 2010
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
Daily EB et al.
Pharmacogenomics, 2009
Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H et al.
Basic & Clinical Pharmacology & Toxicology, 2009
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Singh V et al.
Cancer Investigation, 2008
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J et al.
Clinical Pharmacology and Therapeutics, 2006
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.
García-Martín E et al.
Molecular Diagnosis & Therapy, 2006
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
Nakajima M et al.
Journal of Clinical Pharmacology, 2005
Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population.
Hichiya H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.
Totah RA et al.
Clinical Pharmacology and Therapeutics, 2005
A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.
Ishikawa C et al.
Journal of Human Genetics, 2004
Genetic polymorphisms of CYP2C8 in Japanese population.
Nakajima M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2003
Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A.
Soyama A et al.
Pharmacology & Toxicology, 2002
Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism.
Soyama A et al.
Biological & Pharmaceutical Bulletin, 2001
Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
Yamaguchi H et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 0